Stay updated with the latest progression-free-survival news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on progression-free-survival topics.
, /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in from National Medical (TASE:PMCN) Products Administration (NMPA) for the first domestically developed trophoblast cell-surface antigen 2 (TROP2)-directed antibody"drug conjugate (ADC) sacituzumab tirumotecan (sac-™T, formerly SKB264/MK-2870) for adult patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) who ha ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.